IPO - Nuvectis Pharma, Inc.

Form Type: 424B5

Filing Date: 2025-02-06

Corporate Action: Ipo

Type: New

Accession Number: 000110465925009812

Filing Summary: Nuvectis Pharma, Inc. is offering 2,700,000 shares of its common stock at a public offering price of $5.00 per share, aiming to raise approximately $13.5 million before expenses. The company's common stock is listed on The Nasdaq Capital Market under the symbol 'NVCT.' As of February 4, 2025, the last reported sale price of the common stock was $7.00. The offering includes underwriting discounts totaling $945,000, and an additional option granted to underwriters to purchase an extra 405,000 shares within 30 days, which could increase the total proceeds to approximately $14.4 million if fully exercised. The net proceeds will be allocated toward advancing the clinical development programs for their product candidates NXP800 and NXP900, hiring personnel, capital expenditures, and general corporate uses. Nuvectis Pharma is a clinical-stage biopharmaceutical company focusing on innovative medicines for oncology, currently progressing clinical trials for their lead candidates. The document indicates that an immediate dilution of $3.91 per share will be incurred by new investors due to the offering price versus the firm’s net tangible book value. Delivery of shares is expected on February 6, 2025.

Document Link: View Document

Form Type: 8-K

Filing Date: 2025-02-06

Corporate Action: Ipo

Type: New

Accession Number: 000110465925009813

Filing Summary: On February 5, 2025, Nuvectis Pharma, Inc. entered into an underwriting agreement with Lucid Capital Markets, LLC for a public offering of 2,700,000 shares of its common stock at a public price of $5.00 per share. The Underwriter has also been granted an option to purchase an additional 405,000 shares. The offering is expected to close on February 6, 2025, providing the company with approximately $14.4 million in net proceeds. The offering follows the company's effective shelf registration statement on Form S-3 filed with the SEC. The document includes customary representations and warranties by the Company and outlines obligations including indemnification for liabilities under the Securities Act of 1933. The Company publicly announced the launch and pricing of the offering through press releases on February 4 and 5, 2025, respectively.

Document Link: View Document

Form Type: 424B5

Filing Date: 2025-02-04

Corporate Action: Ipo

Type: New

Accession Number: 000110465925009141

Filing Summary: Nuvectis Pharma, Inc. is conducting an initial public offering of shares of its common stock, with a par value of $0.00001 per share. The offering aims to raise capital to support the development of their lead product candidates, NXP800 and NXP900. The last reported sale price of the company's stock prior to the offering was $6.80 per share. The document outlines the specifics of the offering including public offering price, underwriting discounts, and potential proceeds, though specific figures are not provided in this preliminary prospectus supplement. The underwriter is Lucid Capital Markets, LLC, and an option has been granted to purchase additional shares for 30 days post-offering. The development of both lead candidates involves significant research and clinical trials, and the continued development is contingent on securing adequate funding. Nuvectis has indicated high degrees of risk associated with this investment, driven by their early stage in clinical development, potential dilution of shares, and the inherent uncertainties in biopharmaceutical advances. The offering documents highlight the company's strategies and intentions to advance their biotechnology portfolio while navigating regulatory approvals and commercial viability.

Document Link: View Document